Efficacy and safety of oxcarbazepine and carbamazepine in the treatment of vestibular paroxysmia: a meta-analysis
10.3760/cma.j.cn114015-20240129-00069
- VernacularTitle:奥卡西平与卡马西平治疗前庭阵发症疗效及安全性的meta分析
- Author:
Changbo SHEN
1
;
Wenkuan YANG
;
Linli ZHANG
;
Yamei LIU
;
Mei JIN
Author Information
1. 新乡医学院第三附属医院神经内科，新乡 453003
- Publication Type:Journal Article
- Keywords:
Oxcarbazepine;
Carbamazepine;
Vestibular paroxysmia;
Meta-analysis;
Safety
- From:
Adverse Drug Reactions Journal
2024;26(8):487-492
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To systematically evaluate and compare the efficacy and safety of oxcarbazepine and carbamazepine in the treatment of vestibular paroxysmia (VP).Methods:Randomized controlled trials (RCTs) of oxcarbazepine versus carbamazepine in the treatment of VP, in which the outcome measures included response rate, visual analogue scale for vertigo and the attack frequency, and incidence of adverse events/reactions were collected by searching relevant databases at home and abroad (up to March 2023). The Cochrane Collaboration′s tool for assessing risk of bias was used to evaluate the quality of the included studies. RevMan 5.3 software was used for meta-analysis. The effect sizes of counting data were odds ratio ( OR) and its 95% confidence interval ( CI), and those of the measurement data were mean difference ( MD) and its 95% CI. Results:A total of 7 RCTs and 476 patients were entered in the analysis, including 236 in the oxcarbazepine group and 240 in the carbamazepine group. Meta analysis showed that there were no significant differences in the total effective rate of oxcarbazepine and carbamazepine in the treatment of VP [85.7% (168/196) vs. 85.0% (170/200), OR=1.07, 95% CI: 0.61-1.86], the decrease of visual analogue scale for vertigo after treatment ( MD=0.40, 95% CI: -0.52-1.32) or the reduction of vertigo frequency after treatment ( MD=1.15, 95% CI:-1.78-4.08). However, compared to the carbamazepine group, the overall incidence of adverse events/reactions, the incidence of dizziness/ataxia, and incidence of nausea/vomiting in oxcarbazepine group was significantly lower [13.6% (32/236) vs. 30.8% (74/240), OR=0.34, 95% CI: 0.22-0.55, P<0.001; 2.1%(5/236) vs. 7.9%(19/240), OR=0.32, 95% CI: 0.13-0.76, P=0.01; 2.4%(5/211) vs. 7.1%(15/211), OR=0.38, 95% CI: 0.15-0.95, P=0.04]. Conclusion:Oxcarbazepine and carbamazepine have similar efficacy in the treatment of VP, but oxcarbazepine has better safety with lower incidence of adverse reactions in the nervous system and digestive system.
